• Reversine (A3760): Aurora Kinase Workflow Guide

  2026-09-25

  Reversine (A3760) provides a chemical tool for perturbing Aurora kinase activity in mitotic-regulation and cancer-cell assays. Use it for controlled research experiments—not as a validated cell-line-specific protocol, diagnostic reagent, or medical treatment—and do not treat reported kinase IC50 values as cellular dosing instructions.

• Hoechst 33258 for TNT Tumor Imaging

  2026-09-25

  Use Hoechst 33258 to register nuclei, count cells, and assess DNA content in tumor models studying tunneling nanotubes—without mistaking nuclear fluorescence for KRas transfer or membrane mechanics. This workflow pairs a blue fluorescent DNA stain with confocal imaging and orthogonal controls for more interpretable experiments.

• Aurora A Links SAM Metabolism to Trained Immunity

  2026-09-24

  Li et al. identify Aurora kinase A as a regulator of β-glucan-trained immunity, linking Aurora A inhibition to FOXO3–GNMT activity, reduced S-adenosylmethionine, and weaker inflammatory chromatin marks. The findings connect metabolic control to innate immune memory and show that Aurora A inhibition can also compromise β-glucan-associated tumor growth inhibition in the studied model.

• CENP-E Inhibition as a Probe of Mitotic Fidelity

  2026-09-24

  GSK-923295 offers a precise way to interrogate CENP-E motor function, but chromosome misalignment can arise from more than one centromere defect. By placing direct CENP-E inhibition alongside recent findings on CTCF-dependent centromere maintenance, this article outlines a more discriminating strategy for mitosis and cancer research.

• Gastric Cancer Assembloids Capture Tumor–Stroma Effects

  2026-09-23

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with stromal cell populations obtained from the same tumor. Their findings show that stromal context can alter gene-expression patterns and drug sensitivity, highlighting why tumor-only organoids may not fully represent patient-specific treatment responses.

• PF-573228 FAK Inhibitor Workflow for Cancer Studies

  2026-09-23

  PF-573228 provides a practical way to connect FAK phosphorylation with gastric cancer signaling, cell migration, endothelial behavior, and ferroptosis-related phenotypes. This workflow combines dose-aware pathway validation with orthogonal functional assays and troubleshooting guidance for more defensible mechanism-of-action studies.

• AG-490 and Exosomal SNORD52 in HCC

  2026-09-22

  Explore how AG-490 (Tyrphostin B42) can help test JAK2/STAT6 dependence in exosome-driven hepatocellular carcinoma models. This guide emphasizes causal assay design, pathway selectivity limits, and practical interpretation beyond descriptive signaling studies.

• Rottlerin: PKC Inhibitor Workflows

  2026-09-22

  Rottlerin supports controlled studies of PKCδ-linked signaling, cancer-cell growth, apoptosis, endothelial permeability, and virus entry. This practical guide connects dose selection, time-resolved assays, solvent handling, and orthogonal validation so researchers can distinguish pathway modulation from nonspecific cellular stress.

• Reversine: Aurora Kinase Inhibitor Workflows

  2026-09-21

  Reversine enables controlled interrogation of Aurora kinase signaling, mitotic checkpoint failure, cancer cell proliferation inhibition, and apoptosis induction in cancer cells. This guide connects practical dose-response workflows with indexed gastruloid screening, while clearly separating established product evidence from exploratory assay extensions.

• WM-8014: KAT6A Inhibitor Guide

  2026-09-21

  WM-8014 is a reversible, competitive KAT6A inhibitor with reported nanomolar activity against KAT6A and KAT6B. Product and model-system evidence supports its use for oncogene-induced senescence induction, cell cycle arrest assays, and cancer biology research while defining important limits for formulation and in vivo studies.

• Netarsudil (AR-13324) ROCK–siRNA Workflow

  2026-09-20

  Netarsudil (AR-13324) is more than a ROCK pathway probe: it can connect trabecular meshwork biology with experimental siRNA nanoparticle design. This workflow explains how to prepare, screen, formulate, and troubleshoot Netarsudil-based systems while keeping ocular mechanism and delivery claims appropriately separated.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-09-19

  Song et al. show that murine norovirus repurposes the membrane-rupture factor NINJ1 to release the viral NS1 protein while also permitting broad DAMP release during programmed cell death. The study links caspase-3 cleavage, NINJ1 recruitment to viral replication sites, and NS1–NINJ1 interactions to an unconventional secretion pathway that supports oral infection in mice.

• WM-8014: Mechanism and KAT6A Inhibition

  2026-09-18

  WM-8014 is a reversible, competitive KAT6A inhibitor that targets the acetyl-CoA-binding site of MYST-family histone acetyltransferases. Its reported cellular effects include p16INK4A–p19ARF-associated senescence, cell-cycle arrest, and suppression of KRAS G12V-driven hepatocyte overproliferation without general cytotoxicity in the tested models.

• Dinaciclib: Separating Cell Cycle from Cell Mechanics

  2026-09-18

  Dinaciclib (SCH727965) is a potent multi-CDK inhibitor for cancer research, but its effects extend beyond proliferation. This article presents a mechanistic assay framework for distinguishing cell-cycle arrest, apoptosis induction, and tissue-boundary remodeling using insights from a 2026 Drosophila study.

• Simvastatin (Zocor): Applied Research Workflows

  2026-09-17

  Build reproducible Simvastatin workflows that connect HMG-CoA reductase inhibition with lipid phenotyping, hepatic cancer assays, and cholesterol biology. The approach combines practical stock handling, dose-response design, apoptosis and cell-cycle readouts, and a cautious extension into the NPC2–GPX4 axis highlighted by recent glioblastoma research.

8013 records 1/535 page Next 12345 下5页 Last page